Lowest Price Guaranteed
Slides
201
Last Updated
August 2025
View Count
17994
The global biotechnology market size is valued at 1.57 trillion in 2024 and is poised to reach USD 8.01 trillion by 2035, representing a CAGR of 15.98% during the forecast period.
Biotechnology is a multidisciplinary approach that involves the integration of engineering technologies and natural sciences or living organisms to create useful products. The ongoing technological innovations have led to the development of various scientific disciplines, such as genomics, metabolomics, and proteomics.
North America accounts for the largest share of the biotechnology market, capturing 37.79% of overall revenue share. The growth can be attributed to the extensive research and development activities on advanced drugs and the high expenditure on healthcare in this region. Furthermore, the North American region has also witnessed high penetration and adoption of proteomics, genomics, and cell biology-based platforms by industrial leaders. In the long run, the biotechnology market in Asia-Pacific is anticipated to grow at a faster CAGR rate during the forecast period. This can be attributed to the improvement in healthcare infrastructure, expanding research on drugs, and favorable government initiatives to support R&D processes in recent years.
 |
Based on the type of product, the global biotechnology market is segmented into instruments, reagents and services and software. According to our projection, presently instrument accounts for the highest share of the market, capturing 61.43% of the overall revenue share. This can be attributed to the high demand for biotechnology instruments for disease diagnosis and identification of targeted drugs in laboratories. However, in the long run, reagents and services will grow at a higher CAGR driven by the growing research on advance therapeutics and diagnostics techniques that demands reagents in large quantity.
On the basis of technology, the global market has been segmented into nanotechnology, DNA sequencing, cell-based assay, fermentation, PCR technology, chromatography, tissue engineering, and regeneration. Driven by the growing shift towards personalized medicines, the DNA sequencing segment is anticipated to hold the largest share of the market, capturing around 45% of overall biotechnology market share. The rising government initiatives, including investment in the genetic research area have raised the demand for DNA sequencing technology across the globe. However, in the long run, tissue engineering will grow at a higher CAGR of 13.2% during the forecast period. Researchers are recognizing the therapeutic potential of tissues and cells for designing personalized therapies that can target a broad range of diseases. The growing research on tissues and cells for the development of medicines, tissue engineering, and regeneration is expected to grow at a higher CAGR during the forecast period.
On the basis of applications, the biotechnology market is segmented into healthcare, food and beverage, agriculture, industry processing, and others. The healthcare sector is likely to hold the largest share of the market, capturing 35.76% of overall revenue share. This dominance is primarily due to the growing demand for target specific drugs for the treatment of diseases on molecular level. Furthermore, the growing preferences for customized and cost-effective treatment has contributed to the growth of healthcare segment.
However, in the long run, food and beverage and agriculture will show lucrative growth potential and is estimated to grow at a higher CAGR during the forecast period. This is attributed to the fact that molecular techniques have played a significant role in the development of modified crops that can resist abiotic and biotic stress. Furthermore, the growing preferences for sustainable agriculture and organic food is likely to be the potential reason for high growth rate.
Based on the type of end user, the biotechnology market is segmented into healthcare providers, research and government institutes, and pharmaceutical and biotechnology companies. According to our projection, currently pharmaceutical and biotechnology companies hold the highest share of the market, capturing 49.24% of overall revenue share. The highest growth can be attributed to the growing demand for target specific drugs for the treatment of broad range of applications. Moreover, the growing shift towards personalized medicine and cost-effective therapeutic treatment further contributed towards the highest growth share.
However, in the long run, research and government institutes will show lucrative growth potential and is poised to grow at a higher CAGR of 13.3% during the projected period. This is likely to be the fact that research organizations are emphasizing on the strategic initiatives for the development of innovative drugs as well as diagnostic solutions for the treatment of chronic conditions.
The “Global Biotechnology Market: Industry Trends and Global Forecast, till 2035” report features an extensive study on current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities.
Driven by continuous advancements in technology and ongoing research, the biotechnology market seems highly competitive, featuring the presence of several well-established and new entrants. It is worth noting here that most of the players active in this industry are biopharmaceutical firms that are currently emphasizing advanced drug development and therapies. Rapid advancements in various fields, including pharmaceutical, healthcare, agriculture, and environmental science, have contributed to the growth of the biotechnology industry. Additionally, competitive forces such as strategic collaborations and patent rights, along with extensive networking, are further driving the interest of several industry players in the market.
Advances in gene editing technologies such as CRISPR and genomics have revolutionized the study of diseases at the molecular level for the development of personalized treatment. Further, biopharmaceutical companies are emphasizing the development of recombinant proteins and monoclonal antibodies to treat chronic diseases and cancer. The rising focus on advanced therapies has catered to the attention of key industry leaders who aim to expand research on innovative technologies that aid in the production of new drugs, agricultural products, and industrial processes. For instance, Carisma Therapeutics emerged as a pioneer in the biotech industry, specifically known for its innovations and tech-based approach to find cancer treatments. Recently, the clinical-stage company has put all its attention on leveraging the monocyte cell engineering platform and proprietary macrophage for the development of immunotherapies to treat cancer patients.
Additionally, the growing government initiatives and investment in the biotechnology field have become the key drivers of the industry during the forecast period. For instance, in December 2023, DBT (the Department of Biotechnology) and BIRAC (Biotechnology Industry Research Assistance Council) announced the launch of over 14 innovative biotechnology-based products that are developed by established players and startups across various industries such as medical devices, healthcare diagnostics, agriculture, and industrial biotechnology. As the stakeholders continue to drive innovations in this field, the market is anticipated to grow at a steady rate during the forecast period.
The growing prevalence of chronic disease and cancer has caught the attention of industrial leaders to develop advanced diagnostic technologies that aid in the early detection of diseases. Expert healthcare service providers believe that early detection of diseases can reduce the risk of consequences associated with the diseases and fatality rate. Advances in disease diagnostics technologies such as next generation sequencing, polymerase chain reaction, molecular diagnostics, and genomics support early detection and development of personalized treatment. Further, key players are emphasizing the development of unique diagnostics solutions integrated with AI technology that aid in monitoring disease progression in real-time, thereby enabling healthcare providers to customize treatment plans.
Technological innovations in life science have become a cornerstone to developing new products that aid in the treatment of patients and develop high-quality products in industries and the agriculture sector. It is interesting to note here that pharmaceutical and biopharmaceutical companies have spurred the momentous expansion of the biotechnology market. Innovative technologies such as wearable devices, 3D bioprinting technology, and the incorporation of biosensors have opened a gateway for the development of personalized medicines. Further, the integration of biosensors in health monitoring devices enables remote monitoring of pulse, body temperature, and blood pressure and aids in providing treatment on time.
Moreover, 3D bioprinting technology utilizes live cells for the development of tissues and organs required to regenerate body cells of body parts including heart and liver. The ability to create tissues and cells has opened new opportunities for key companies active in the industry to develop new technologies based on AI and machine learning for real-time analysis.
Chemical-based fertilizers and pesticides have caused huge damage to the groundwater table, reduced soil quality, and even resulted in diseases. The negative consequences of using chemical fertilizers and pesticides for crop production have shifted farmers towards organic and genetically modified crops. Biotechnology solutions such as genetic engineering and recombinant technology enable researchers to alter genes to achieve desired crops that hold the ability to resist pests, improve nutrition content, and have higher drought tolerance. For instance, BT crops, also known as genetically engineered plants, contain BT toxin (obtained from the bacteria Bacillus Thuringiensis), so plants can resist insects' attack naturally.
Furthermore, growing interest in sustainable agriculture practices increased the demand for biotechnology solutions that aid in the development of biofertilizers and biopesticides. For instance, Syngenta (a leading producer of sustainable biofertilizers) committed to making a capital investment of USD 2 billion in sustainable agricultural breakthroughs by 2025. The investment will be utilized in the development of new biotechnology-based solutions and businesses that transform the agriculture industry's future sustainably. Additionally, Syngenta has committed to bringing sustainable products such as biocontrol and biostimulants to protect plants from pests and diseases naturally.
The biotechnology market has witnessed unprecedented growth owing to the rising funding and investments by various government and industrial leaders active in this field. In 2023, Quotient Therapeutics raised an investment of USD 50 million from Flagship Pioneering. The funds have been used to advance its genome sequencing technology, Nanoseq, which has been licensed by Wellcome Sanger Institute. The technology has been utilized for the identification of genetic variations at the cellular level and poses the ability to isolate cells that accumulate cancer-driven mutations. Moreover, in May 2023, ReNAgade Therapeutics raised a USD 300 million series A financing round focusing on the development of RNA-based therapeutics. The company is aiming to harness the power of gene editing by combining its RNA platform for editing, coding, and gene inserting to develop advanced transformative medicine.
Additionally, some startup biotech companies are entering into partnerships and collaborations to drive innovations in this field. For instance, Ginkgo Bioworks has partnered with several companies, such as Novartis and Bayer, and received funding from investors, including Viking Global Investors and Bill Gates. The company has raised a total of USD 800.4 million from fundraising rounds. It is highly committed to leveraging advanced technologies to create sustainable and environment-friendly research alternative protein, biofuels, dairy products, and chemicals. The ongoing investments and partnerships will continue to drive biotechnology market growth.
The global biotechnology market is valued at 1.57 trillion in 2024 and is poised to reach USD 8.01 trillion by 2035. This lucrative growth is primarily due to the growing demand for advance technologies including molecular technologies across pharmaceutical, healthcare, agriculture and industrial leaders for the development of innovative products. Driven by the ongoing demand, the market will continue to expand at a higher CAGR of 15.98% during the forecast period.
Examples of the leading players active in the industry (the complete list of the companies is available in full report) included Abbott Laboratories, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Gilead Sciences, Johnson & Johnson, Lonza, Merck, Novo Nordisk, Novartis, Pfizer, Roche, and Sanofi. This market report includes an easily searchable excel database of all the companies active in the biotechnology industry and details on the key players established worldwide.
The market research report covers an extensive study of various companies that are currently active in the global biotechnology industry across various segments, as mentioned below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2018 | |
| Forecast Period | Till 2035 | |
| Market Size 2035 | USD 8.01 trillion | |
| Market CAGR | 15.98% | |
| Type of Product |
|
|
| Type of Technology |
|
|
| Type of Application |
|
|
| Type of End User |
|
|
| Geographical Region |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of the biotechnology market report was to estimate the current market size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
The biotechnology market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as distribution by type of product (instruments, reagents and services, and software), type of technology (nanotechnology, tissue engineering and regeneration, DNA sequencing, cell-based assay, fermentation, PCR technology, chromatography and other technologies), type of application (healthcare, food and beverage, agriculture, industrial processing and other applications), type of end user (healthcare providers, research and government institutes, and pharmaceutical and biotechnology companies), geography (North America, Europe, Asia-Pacific, and Rest of the World) and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three biotechnology market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution. All actual figures have been sourced and analyzed from publicly available information forums and secondary research discussions. Financial figures mentioned in this market research report are in USD unless otherwise specified.
Several recent developments have taken place in this field. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.